RPS6KA1 and non-small cell lung carcinoma: Besides osimertinib, CO1686 (10-1000 nM) and erlotinib (10-1000 nM) similarly suppressed ERK and p90RSK phosphorylation, decreased DR4 levels, and induced PARP cleavage in these two sensitive EGFRm NSCLC cell lines (Figure 1C).